ZNF169

ZNF169 is a Krüppel-type (C2H2) zinc finger transcription factor, originally mapped to chromosome 9q22 (PMID:9186526), that directly binds target gene promoters to upregulate their transcription. ChIP and luciferase reporter assays demonstrate that ZNF169 activates the promoters of ANKZF1, FBXW10, and CDK19, and rescue experiments confirm that these targets mediate ZNF169-driven cancer cell proliferation, migration, and tumor growth in colorectal, thyroid, and hepatocellular carcinoma models (PMID:38666541, PMID:39875985, PMID:39868893).

1. 1997 Medium

   Identification of ZNF169 as a novel Krüppel-type zinc finger gene and its chromosomal localization to 9q22 established the gene's existence and structural classification but left its function entirely unknown.

   Evidence PFGE and FISH mapping of a new C2H2 zinc finger gene in human genomic DNA

   PMID:9186526

   Open questions at the time

   • No functional or transcriptional data were generated
   • No target genes or DNA-binding specificity identified
   • Expression pattern across tissues not characterized
2. 2024 Medium

   Demonstration that ZNF169 directly binds the ANKZF1 promoter and transcriptionally activates it established ZNF169 as a bona fide transcriptional activator and linked it to colorectal cancer cell proliferation through a specific downstream effector.

   Evidence ChIP-qPCR, dual luciferase reporter assay, siRNA knockdown, overexpression, and rescue experiments in colorectal cancer cell lines

   PMID:38666541

   Open questions at the time

   • DNA-binding motif or consensus sequence for ZNF169 not defined
   • Findings from a single laboratory; independent replication lacking
   • Physiological (non-cancer) role of ZNF169 not addressed
3. 2025 Medium

   Extension to thyroid carcinoma and hepatocellular carcinoma with two additional direct targets (FBXW10 and CDK19) reinforced the model of ZNF169 as a general transcriptional activator promoting tumor cell proliferation and migration across cancer types.

   Evidence ChIP-PCR, luciferase assays, knockdown/overexpression rescue experiments in vitro and in vivo (xenograft) in thyroid and liver cancer models

   PMID:39868893 PMID:39875985

   Open questions at the time

   • All three target studies originate from overlapping research groups; independent validation is needed
   • Genome-wide binding profile (e.g., ChIP-seq) has not been reported
   • Mechanism of transcriptional activation (cofactor recruitment, activation domain) is unknown

• The DNA-binding specificity, cofactor requirements, post-translational regulation, and normal physiological function of ZNF169 outside cancer contexts remain uncharacterized.
• No consensus binding motif determined
• No interacting coactivators or chromatin-remodeling partners identified
• No loss-of-function studies in normal tissues or model organisms